<unk>  should not be taken by women with severe liver diseases because of its CYP mediated metabolism. It has not been studied in women under the age of 18. It is also not recommended for women with severe asthma receiving glucocorticoid treatment because it has shown antiglucocorticoid effects in animal studies. Pregnancy Unlike levonorgestrel, and like mifepristone,<unk>  is embryotoxic in animal studies. Before taking the drug, a pregnancy must be excluded. The EMA proposed to avoid any allusion to a possible use as an abortifacient in the package insert to avert off-label use. It is unlikely that<unk>  could effectively be used as an abortifacient, since it is used in much lower doses (30 mg) than the roughly equipotent mifepristone (600 mg), and since mifepristone has to be combined with a prostaglandin for the induction of abortion. However, data on embryotoxicity in humans are very limited, and it is not clear what the risk for an abortion or for teratogenicity (birth defects) is. Of the 29 women studied who became pregnant despite taking<unk> , 16 had induced abortions, six had spontaneous abortions, six continued the pregnancies, and one was lost to follow-up. Lactation It is not recommended to breast feed within seven days of taking the drug since<unk>  is are excreted into the breast milk, and possible effects on the infant have not been studied.
Ulipristal acetate
Macimorelin
Linagliptin
Saxagliptin
Sitagliptin
Liraglutide
Vildagliptin
Lumacaftor